GTCR Acquires Zentiva from Advent
Analysis based on 7 articles · First reported Apr 09, 2026 · Last updated Apr 12, 2026
The acquisition of Zentiva by GTCR is expected to positively impact the pharmaceutical and healthcare sectors by fostering growth in the generics market. This transaction highlights the ongoing private equity interest in healthcare, aiming to enhance access to affordable medicines and support sustainable healthcare systems.
GTCR, a leading private equity firm, has completed the acquisition of Zentiva, a prominent European generics pharmaceutical company, from Advent International. Zentiva specializes in the development, manufacturing, and supply of generic, branded specialty, and over-the-counter medicines across over 40 countries. GTCR plans to partner with Zentiva's management team, led by CEO Steffen Saltofte and Executive Chairperson Kieran Murphy, to drive the company's next phase of growth. This will involve continued investment in new product development, portfolio expansion, and broader geographic reach, with a strategic focus on improving patient access to essential medicines and supporting sustainable healthcare systems. The acquisition underscores GTCR's long-standing commitment to healthcare investments and Zentiva's critical role in delivering cost-effective therapies at scale.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard